




CONTENTS


Introduction	I
<i>Jeanne Moldenhauer</i>	
References	II
2 Regulatory Basis for FDA Inspections	I3
<i>Jeanne Moldenhauer</i>	
Responsibilities of the FDA	I3
Review of New Products	14
Monitoring Products on the Market	14
Development of Standards and Regulations	15
Research Activities	15
Enforcement Activities	15
The Food, Drug and Cosmetic Act	16
The Bill of Rights	17
Constitutional Challenges to the Authority to Inspect Facilities	17
FDA Responsibilities	19
FDA Inspections	20
FDA Investigators	22
The FDA Investigator's Role During an Inspection	22
Regulatory Notes	22
Team Inspections	23
FDA's Inspection Preparation	24
Pre-announcements	24





Notice of Inspection	25
Follow-up Inspections Conducted via Court Order	25
Inspections when Criminal Acts are Contemplated	26
Preliminary Questions Asked	26
Inspectional Approach	26
Typical Inspection Techniques	27
Fact-Finding Mission	28
Sample Collection	29
Interview Techniques	29
Reporting Observations	30
Annotation of the FD-483	31
Wrap-Up Meetings (Discussions with Management)	31
Establishment Investigation Report (EIR)	31
Affidavits	32
Commonly Used FDA Inspection Forms	32
Pre-Approval Inspections (PAIs)	33
Refusing an Inspection	33
References	34
3 Systems-Based Inspections	35
<i>Jeanne Moldenhauer</i>	
Objectives of Systems-based Drug Inspections	36
Strategy	37
Systems for Audit During Inspection	38
Quality System	38
Facilities and Equipment System	39
Materials System	39
The Production System	39
The Packaging and Labeling System	39
The Laboratory Control System	39
Inspection Options	40
Full Inspection Option	40
Abbreviated Inspection Option	40
Selection of the Systems to be Inspected	40
Product Classes	41
Other Types of Inspections	42
Compliance Inspections	42
State of Control	42
Out-of-Control	42
References	42







Contents


v


4 The Quality System	73
<i>David A. Henninger</i>	
Introduction	73
The Quality System — Management Responsibility	75
Introduction	75
Design Considerations	75
Inspection of Management Responsibility	76
Quality Systems — Drug Product Reviews	83
Introduction	83
System Design Considerations	83
Inspection Guidance	83
Quality System — Drug Product Complaints	88
Introduction	88
System Design Considerations	88
Inspection Guidance	92
Quality Systems — Discrepancy and Failure Investigations	100
Introduction	100
Design Considerations	100
Inspection Guidance	101
Quality Systems — Change Control	105
Introduction	105
Design Considerations	105
Inspection Guidance	110
Quality Systems — Product Improvement Projects	116
Introduction	116
Design Considerations	116
Inspection Guidance	116
Quality Systems — Reprocess/Rework	119
Introduction	119
Design Considerations	119
Inspection Guidance	119
Quality Systems — Returns and Salvage	124
Introduction	124
Design Considerations	124
Inspection Guidance	125
Quality Systems — Rejects	130
Introduction	130
Design Considerations	130
Inspection Guidance	130
Quality Systems — Stability Testing	134
Introduction	134






Design Considerations	134
Inspection Guidance	134
Quality System — Quarantine Products	142
Introduction	142
Design Considerations	142
Inspection Guidance	142
Quality System — Validation and Revalidation	147
Introduction	147
Design Considerations	147
Inspection Guidance	148
Quality System — Training and Qualification of Quality	153
Unit Employees	153
Introduction	153
Design Considerations	153
Inspection Guidance	155
References	159
Bibliography	159
5 The Facilities and Equipment System	163
<i>Michael Millin</i>	
Facility Design	164
Raw Material Flow	167
Finished Product and Components	167
Lighting	177
Ventilation, Air Filtration, Air Heating and Cooling	178
§211.48 Plumbing	182
Sewage and Refuse	184
Washing and Toilet Facilities	184
Sanitation	185
Maintenance	186
Equipment	187
Equipment Design, Size, and Location	187
Equipment Construction	188
Equipment Cleaning and Maintenance	188
Calibration	190
Automatic, Mechanical, and Electronic Equipment	191
Conduct of the Inspection	192
Critical Concerns	195
References	197






6	The Materials System	203
	<i>Seth Pyers</i>	
Areas an Inspection is Expected to Cover 203		
Considerations for Assessing Compliance for these Systems 205		
Materials System Overview 205		
Standard Materials 206		
Written and Approved Procedures 206		
Training and Qualification of Personnel 207		
Identification of Components, Containers and Closures 207		
Inventory of Components, Containers and Closures 207		
Storage Conditions 207		
Quarantine of Materials until Tested and/or Examined 207		
Specific Identity Testes for Each Lot of Components 208		
Visual Identification Test for Each Lot 208		
Validation of Vendor Supplied Test Results 208		
Materials are Rejected when Criteria are not Met 208		
Determine When and How to Retest Lots of Materials 208		
Procedures Ensure First-In-First-Out of Components 208		
Surfaces, Containers and Products are Mutually Non-Reactive 209		
Change Control 209		
Inventory Control Software 209		
Part II Compliance for Automated Data Handling Systems 210		
Record All Finished Products by Lots 211		
Document Investigations 211		
Utility Provided Materials 212		
Water Production Sources 212		
Guide to Inspection High Purity Water Systems 213		
Systems Design 213		
Microbial Limits USP High Purity and WFI Hot, Cold and Ambient 213		
Pretreatment 214		
Flocculation 214		
Reverse Osmosis 215		
Distillation 216		
Biofilms 219		
High Purity Water Systems Validation 224		
Inspection Strategy 225		
Clean Steam Systems 226		
Solvents 226		
Medical Grade Gases 227		





Examples of Significant and/or Trend of Deficiencies	227
Recent Regulatory Findings	228
References	228
7 The Production System	231
<i>Michele Conway and Robert Ferer</i>	
Training/Qualification of Personnel	233
Control System for Implementing Changes in Process	234
Adequate Procedure and Practice for Charge-in of Components	236
Formulation/Manufacturing at Not Less Than 100%	237
Identification of Equipment with Contents, and Where	
Appropriate Phase of Manufacturing and/or Status	238
Validation and Verification of Cleaning/Sterilization/	
Depyrogenation of Containers and Closures	239
Calculation and Documentation of Actual Yields and	
Percentage of Theoretical Yields	241
Contemporaneous and Complete Batch Production	
Documentation	242
Established Time Limits for Completion of Phases of Production	243
Implementation and Documentation of In-Process Controls,	
Tests, and Examinations (e.g., pH, adequacy of mix, weight	
variation, clarity)	244
Justification and Consistency of In-Process Specifications	
and Drug Final Specifications	245
Prevention of Objectionable Microorganisms in Non-Sterile	
Drug Products	246
Adherence of Preprocessing Procedures (e.g., set-up, line	
clearance, etc.)	247
Equipment Cleaning and Use Logs	248
Master Production and Control Records/Batch Production	
and Control Records	249
Process Validation, Including Validation and Security of	
Computerized or Automated Processes	250
Change Control: The Need for Revalidation Evaluated	252
Documented Investigation into any Unexpected Discrepancy	253
References	254

8	The Packaging and Labeling System	257
	<i>Jeanne Moldenhauer</i>	
	Areas Expected to be Covered in an Inspection	257
	Considerations for Assessing Compliance for these Systems	259
	Evidence of Written Procedures	259
	Training and Qualification of all Affected Personnel	259
	Procedure for Acceptance of Packaging and Labeling Materials	259
	Effective Change Control System for Implementing Changes in Packaging and Labeling Operations	260
	Adequate Storage for Labels and Labeling (both approved and those returned after Issuance)	260
	Control of Labels that are Similar in Size, Shape, and Color for Different Products at the Site	261
	If Cut Labels are used for Finished Products for Immediate Containers that are Similar in Appearance without Some Type of 100% Electronic or Visual Verification System or Use of Dedicated Lines	261
	Verification that Gang Printing of Labels is Not Performed, Unless the Labels are Differentiated by Size, Shape or Color	261
	Control Procedures are Established and Followed if Filled Unlabeled Containers are Produced that are Later Labeled under Multiple Private Labels	262
	Adequate Packaging Records are Available that Include Specimens of All Labels Used for Each Product and Lot	262
	Control Procedures are Established and Followed for Issuance of Labeling, and that there is Appropriate Examination of Issued Labels and Reconciliation of Used Labels	262
	Examination of Labeled Finished Product is Conducted Adequate Inspection (proofing) of Incoming Labeling Materials	262
	Appropriate Use of Lot Numbers on Labels, and Destruction of Excess Labeling Bearing Lot or Control Numbers	263
	Physical and/or Spatial Separation Exists Between Different Labeling and Packaging Lines	263
	Monitoring of Printing Devices Associated with Manufacturing Lines is Conducted	279
	Line Clearance and Inspection is Performed and Documented	263





Adequate Expiration Dates are Present on the Label	264
Conformance to Tamper-Evident Packaging (TEP)	
Requirements, as Required per 21 CFR §211.132 and	
Compliance Policy Guide No. 7132a.17	264
Appropriate Validation of Packaging and Labeling	
Operations is Conducted including Validation and	
Security of Computerized Processes	264
Documented Investigations are Performed for any	
Unexpected Discrepancy	264
Examples of Significant and/or Trend of Deficiencies	265
Recent Regulatory Findings	265
References	265
9 The Laboratory System	267
<i>Jeanne Moldenhauer</i>	
Areas Expected to be Covered in an Inspection	267
Evidence of Written Procedures	269
Training and Qualification of all Affected Personnel	269
Adequacy of Staffing for Laboratory Operations	269
Adequacy of Equipment and Facility for Intended Use	270
Calibration and Maintenance Programs for Analytical	
Instruments and Equipment	271
Validation and Security of Computerized or Automated	
Processes	272
Reference to Standards, Source, Purity and Assay, and	
Tests Establish Equivalency to Current Official Reference	
Standards, as Appropriate	272
System Suitability Checks on Chromatographic Systems	
(e.g., GC or HPLC)	273
Specifications, Standards, and Representative Sampling Plans	273
Adherence to the Written Methods of Analysis	273
Validation or Verification of Analytical Methods	273
Control System for Implementing Changes in Laboratory	
Operations	274
Required Testing is Performed on the Correct Samples	275
Documented Investigation into any Unexpected Discrepancy	275
Complete Analytical Records from All Tests and Summaries	
of Results	275
Quality and Retention of Raw Data (e.g., chromatographs	
and spectra)	276







Correlation of Result Summaries to Raw Data; Presence of Unused Data	276
Adherence to an Adequate OOS Procedure which includes Timely Completion of the Investigation	276
Adequate Reserve Samples; Documentation of Reserve Sample Examination	277
Stability Testing Program, including Demonstration of Stability Indicating Capability of the Test Methods	277
Examples of Significant and/or Trend of Deficiencies	277
Recent Regulatory Findings	278
Issues with Procedures for OOS	286
Environmental Monitoring and Control Issues	386
Media Fill Observations	286
Reference	287
10 Evaluating Your Facility for Compliance	289
<i>Jeanne Moldenhauer</i>	
Who Should Perform Assessments	290
Typical Assessment Procedures	290
Audit Preparation	290
During the Audit	291
Completing the Assessment	292
Assessment Report	292
Assessment Follow-Up	292
Retention of Assessment Reports	293
Example of an Audit Checklist	294
11 Preparing for a FDA Systems-Based Inspection	323
<i>Jeanne Moldenhauer</i>	
Why Prepare?	323
Historical Methods Used for Inspection Preparation	324
The Current Situation	325
Identify Key Employees and Train Them	326
Interacting with the FDA During the Inspection	327
What to Expect During the Interview Process	328
Aids to Training and Answering Questions During the Audit	328
History of Company and Organization Charges	328
Flow Charts	329





Sterile Process Validation Documentation Packages	330
Key indices	330
Standardization of Documentation	330
Technical Glossary	330
Questions to Ask the FDA	331
Information that Should be Conveyed to the Inspector	331
Practice Tours of the Facility	332
Self-Audit and Know Your Vulnerabilities	332
Prepare for the FDA Areas of Focus	333
Inspectional Guidance Documents	333
Know Your Company's Policies	334
Documentation	334
Requests for Samples	335
Mock Inspections	336
I Know I Have a Problem. Now What?	336
Simple Rules of Etiquette to Use During an Inspection	337
Handling Difficult Inspectors	338
Learn from the Mistakes of Others	339
Observations for the Quality System	339
Observations for the Laboratory System	340
Observations for the Facilities and Equipment System	340
Observations for the Production System	340
Acknowledgements	341
References	341
12 Managing of Regulatory Inspections	345
<i>Jeanne Moldenhauer</i>	
Who May Inspect the Facility?	345
What Requirements Allow the Government Inspection?	336
What is the Purpose of the Audit?	347
Are There Company Policies or Procedures that will Define	
What Investigators May Do During the Inspection?	348
What's Your Job?	349
How Do I Handle Documentation?	351
What Could Go Wrong?	351
Conclusion	351
Acknowledgements	351





13	Concluding an Inspection and Handling Inspection Findings	353
	<i>Jeanne Moldenhauer</i>	
	The Exit Discussion	354
	Reporting of Observations, the FDA-483	355
	General Principles for FDA-483 Observations	355
	Annotation of Observations	356
	Impact of these Observations	356
	Freedom of Information (FOI)	356
	Writing Observations	357
	Triggers to Observations	357
	Non-reportable Observations	358
	Determining the Significance of FDA-483 Observations	358
	Handling Adverse Findings	359
	Written Response to the FDA-483	359
	Dispute Resolution	360
	Evaluation Compliance with Corrective Action Program	
	Established	360
	Warning Letters	361
	On-going Evaluations	361
	References	361
	Glossary	363
	Author Biographies	373
	Index	

